{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:43:16Z","timestamp":1792176196308,"version":"4.4.0"},"reference-count":79,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hospital Corporation of America, West Florida Division Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscles"],"abstract":"<jats:p>Dermatomyositis (DM) is a prototypic idiopathic inflammatory myopathy in which characteristic skin disease frequently precedes or parallels muscle involvement and signals risks such as interstitial lung disease (ILD) and malignancy. This literature review integrates recent advances across dermatology, neuromuscular medicine, and immunology to refine diagnosis and management. We surveyed the literature from 2000 to 2025, prioritizing randomized trials, large cohorts, and translational studies that spanned classic and juvenile DM, amyopathic\/hypomyopathic variants, and overlap phenotypes. Key insights include the diagnostic weight of pathognomonic cutaneous lesions with nailfold microangiopathy; the utility of myositis-specific autoantibodies for endotyping and risk (e.g., anti-TIF1-\u03b3\/anti-NXP2 and cancer, anti-MDA5 and rapidly progressive ILD); and the value of myxovirus-resistance protein A (MxA) immunohistochemistry and muscle MRI patterning (including distinctions from immune-mediated necrotizing myopathy) when enzymes are normal, or biopsies are treatment-modified. Management is anchored in early steroid-sparing immunosuppression tailored to phenotype, with evidence for IVIG in active DM and growing support for JAK inhibition, particularly in interferon-high or anti-MDA5 ILD, alongside selective use of calcineurin inhibitors and rituximab, with plasma exchange considered for refractory, rapidly progressive ILD. We highlight risk-stratified malignancy screening (IMACS 2023) and complications, including calcinosis, lipodystrophy, and chronic cutaneous damage. Skin-led recognition coupled with antibody-guided, phenotype-directed therapy and interdisciplinary care offers a pragmatic precision framework to improve outcomes and reduce long-term disability.<\/jats:p>","DOI":"10.3390\/muscles4040058","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:37:02Z","timestamp":1764952622000},"page":"58","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An Update on Dermatomyositis and Related Inflammatory Myopathies: Cutaneous Clues, Skeletal Muscle Involvement, and Advances in Pathogenesis and Treatment"],"prefix":"10.3390","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5794-3124","authenticated-orcid":false,"given":"Andres","family":"Parga","sequence":"first","affiliation":[{"name":"Hospital Corporation of America, Florida Healthcare, Graduate Medical Education, Morsani College of Medicine, University of South Florida, 11375 Cortez Blvd, Brooksville, FL 34613, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Ratra","sequence":"additional","affiliation":[{"name":"Hospital Corporation of America, Florida Healthcare, Graduate Medical Education, Morsani College of Medicine, University of South Florida, 11375 Cortez Blvd, Brooksville, FL 34613, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Luu","sequence":"additional","affiliation":[{"name":"Hospital Corporation of America, Florida Healthcare, Graduate Medical Education, Morsani College of Medicine, University of South Florida, 11375 Cortez Blvd, Brooksville, FL 34613, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e000507","DOI":"10.1136\/rmdopen-2017-000507","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: A methodology report","volume":"3","author":"Bottai","year":"2017","journal-title":"RMD Open"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/S2665-9913(23)00322-3","article-title":"Idiopathic inflammatory myopathies: Current insights and future frontiers","volume":"6","author":"Connolly","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jaad.2024.08.075","article-title":"Dermatomyositis","volume":"92","author":"Helm","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","first-page":"359","article-title":"Current concepts and advances in dermatomyositis: A dermatological perspective","volume":"41","author":"Lim","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1093\/rheumatology\/keae630","article-title":"Type I interferon biomarker in idiopathic inflammatory myopathies: Associations of Siglec-1 with disease activity and treatment response","volume":"64","author":"Kamperman","year":"2025","journal-title":"Rheumatology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Qian, J., Li, R., Chen, Z., Cao, Z., Lu, L., and Fu, Q. (2023). Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1151695"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/art.42526","article-title":"The Type I Interferon Signature Reflects Multiple Phenotypic and Activity Measures in Dermatomyositis","volume":"75","author":"Tabata","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: Pathogenesis and clinical progress","volume":"20","author":"Lu","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00281-025-01054-9","article-title":"Dermatomyositis: Focus on cutaneous features, etiopathogenetic mechanisms and their implications for treatment","volume":"47","author":"Ali","year":"2025","journal-title":"Semin. Immunopathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/acr.24786","article-title":"Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-Based Cohort Study","volume":"75","author":"Kronzer","year":"2023","journal-title":"Arthritis Care Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/jamadermatol.2022.3112","article-title":"Incidence of Dermatomyositis in a Nationwide Cohort Study of US Veterans","volume":"158","author":"Bolender","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jamadermatol.2021.5841","article-title":"Risk-Based Screening for Cancer in Patients with Dermatomyositis: Toward a More Individualized Approach","volume":"158","author":"Vaughan","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41584-024-01188-4","article-title":"An update on autoantibodies in the idiopathic inflammatory myopathies","volume":"21","author":"Allameen","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_15","first-page":"364","article-title":"An update on myositis autoantibodies and insights into pathogenesis","volume":"43","author":"Wang","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","article-title":"Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies","volume":"20","author":"Wolstencroft","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12016-022-08922-4","article-title":"Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis","volume":"63","author":"Niemczyk","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1067\/mjd.2002.120620","article-title":"Amyopathic dermatomyositis: Retrospective review of 37 cases","volume":"46","author":"Pakzad","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1093\/rheumatology\/keab433","article-title":"The scleromyositis phenotype. Lessons from a multicentre international cohort of anti-PM\/Scl\u2013positive patients","volume":"60","year":"2021","journal-title":"Rheumatology"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Giannini, M., Ellezam, B., Leclair, V., Lefebvre, F., Troyanov, Y., Hudson, M., Sen\u00e9cal, J.L., Geny, B., Landon-Cardinal, O., and Meyer, A. (2023). Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.974078"},{"key":"ref_22","first-page":"e78002","article-title":"Polymyositis-Like Myopathy with Anti-PL-12 Antibody Positivity and Coexisting Antiphospholipid Syndrome: Diagnostic and Management Challenges in the Absence of Systemic Features","volume":"17","author":"Parga","year":"2025","journal-title":"Cureus"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Patel, P., Marinock, J.M., Ajmeri, A., and Brent, L.H. (2024). A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084453"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.21037\/jtd-20-3328","article-title":"A narrative review of interstitial lung disease in anti-synthetase syndrome: A clinical approach","volume":"13","author":"Sawal","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Julien, S., Challier, I., Malleter, M., Jouen, F., Drouot, L., and Boyer, O. (2024). Immune-Mediated Necrotizing Myopathy (IMNM): A Story of Antibodies. Antibodies, 13.","DOI":"10.3390\/antib13010012"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ma, X., and Bu, B.T. (2022). Anti-SRP immune-mediated necrotizing myopathy: A critical review of current concepts. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1019972"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103468","DOI":"10.1016\/j.autrev.2023.103468","article-title":"Anti-HMGCR immune-mediated necrotising myopathy: Addressing the remaining issues","volume":"22","author":"Khoo","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/rheumatology\/keaa801","article-title":"Polymyositis: Is there anything left? A retrospective diagnostic review from a tertiary myositis centre","volume":"60","author":"Lilleker","year":"2021","journal-title":"Rheumatology"},{"key":"ref_29","unstructured":"Ufkes, N. (2025, August 11). Dermatomyositis. UtahDERM. Department of Dermatology, University of Utah School of Medicine. Available online: https:\/\/utahderm.med.utah.edu\/diagnoses\/dermatomyositis\/."},{"key":"ref_30","first-page":"145","article-title":"The Holster Sign: An Overlooked Cutaneous Finding in the Diagnosis of Dermatomyositis","volume":"4","author":"Cooper","year":"2015","journal-title":"J. Arthritis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jaad.2019.02.027","article-title":"Tracking changes in nailfold capillaries during dermatomyositis treatment","volume":"81","author":"Argobi","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/rheumatology\/keae677","article-title":"The role of nailfold video-capillaroscopy in the assessment of dermatomyositis","volume":"64","author":"Xu","year":"2025","journal-title":"Rheumatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jid.2022.05.230","article-title":"223 Evaluation of nailfold capillaries in dermatomyositis using a dermatoscope","volume":"142","author":"Dan","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjd.16498","article-title":"Itch in dermatomyositis: The role of increased skin interleukin-31","volume":"179","author":"Kim","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/brain\/aww122","article-title":"Microvascular alterations and the role of complement in dermatomyositis","volume":"139","author":"Lahoria","year":"2016","journal-title":"Brain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/archderm.1968.01610120030004","article-title":"Histopathology of the Skin in Dermatomyositis: A Histopathologic Study of 55 Cases","volume":"97","author":"Janis","year":"1968","journal-title":"Arch. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: Clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Xiao, P.P., Fan, W., Chen, X.Y., Li, K.C., Li, T.T., and Dong, Z.G. (2024). MDA5-positive dermatomyositis without muscle weakness and rash: A case report and literature review. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1482350"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00401-023-02669-8","article-title":"Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases","volume":"147","author":"Nelke","year":"2024","journal-title":"Acta Neuropathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.2147\/JIR.S433239","article-title":"Sarcoplasmic Myxovirus Resistance Protein A: A Study of Expression in Idiopathic Inflammatory Myopathy","volume":"16","author":"Waisayarat","year":"2023","journal-title":"J. Inflamm. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/ITT.S381472","article-title":"Dermatomyositis: Practical Guidance and Unmet Needs","volume":"13","author":"Cassard","year":"2024","journal-title":"ImmunoTargets Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"105257","DOI":"10.1016\/j.nmd.2024.105257","article-title":"Magnetic resonance imaging in idiopathic inflammatory myopathies: Deciphering the pattern of muscle involvement","volume":"47","author":"Sridhar","year":"2025","journal-title":"Neuromuscul. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wilks, A.W., Vakil-Gilani, K.M., Rooney, W.D., Choi, D., Ghetie, D., and Chahin, N. (2025). MRI patterns of thigh muscle involvement in immune-mediated necrotizing myopathy and dermatomyositis. BMC Rheumatol., 9.","DOI":"10.1186\/s41927-025-00500-3"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/mr\/roae070","article-title":"Contrast of muscle magnetic resonance imaging and pathological findings of muscle tissue in patients with anti-aminoacyl transfer RNA synthetase antibodies","volume":"35","author":"Takei","year":"2025","journal-title":"Mod. Rheumatol."},{"key":"ref_45","first-page":"e71821","article-title":"Long-Term Dysphagia Severity in Patients with Idiopathic Inflammatory Myopathy: A Single-Center Retrospective Study","volume":"16","author":"Ohmura","year":"2024","journal-title":"Cureus"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"O\u017cga, J., Ostrog\u00f3rska, M., Wojciechowski, W., and \u017buber, Z. (2024). Diagnostic Value of Whole-Body MRI in Pediatric Patients with Suspected Rheumatic Diseases. Medicina, 60.","DOI":"10.3390\/medicina60091407"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.1093\/rheumatology\/keaf335","article-title":"Advances in JDM: Biomarker and MRI sensitivity, outcomes and steroid management in a Dutch national prospective cohort","volume":"64","author":"Veldkamp","year":"2025","journal-title":"Rheumatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1212\/WNL.0000000000003568","article-title":"Sarcoplasmic MxA expression: A valuable marker of dermatomyositis","volume":"88","author":"Uruha","year":"2017","journal-title":"Neurology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/mus.28066","article-title":"Myxovirus resistance protein A (MxA) expression in myositides: Sarcoplasmic expression is common in both dermatomyositis and lupus myositis","volume":"69","author":"Xing","year":"2024","journal-title":"Muscle Nerve"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"152408","DOI":"10.1016\/j.semarthrit.2024.152408","article-title":"Effect modification of cancer on the association between dysphagia and mortality in early idiopathic inflammatory myopathies","volume":"65","author":"Leclair","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e40605","DOI":"10.1097\/MD.0000000000040605","article-title":"A retrospective study for clinical characteristics of 293 patients with dermatomyositis","volume":"103","author":"Xie","year":"2024","journal-title":"Medicine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100420","DOI":"10.1016\/j.clinsp.2024.100420","article-title":"NXP-2 positive dermatomyositis with marked dysphagia following an insect bite","volume":"79","author":"Bombardi","year":"2024","journal-title":"Clinics"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Nombel, A., Fabien, N., and Coutant, F. (2021). Dermatomyositis with Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.773352"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13075-025-03485-z","article-title":"Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease","volume":"27","author":"Zhao","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"103334","DOI":"10.1016\/j.autrev.2023.103334","article-title":"The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review","volume":"22","author":"Gasparotto","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/atm-25-44","article-title":"Dazukibart for dermatomyositis: Expanding the therapeutic arsenal","volume":"13","author":"Mammen","year":"2025","journal-title":"Ann. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: Proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","article-title":"International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: An International Myositis Assessment and Clinical Studies Group (IMACS) initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular Deposition of Complement Membrane Attack Complex in Dermatomyositis","volume":"314","author":"Kissel","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"432","DOI":"10.21037\/atm-20-5215","article-title":"Dermatomyositis and malignancy: Should all patients with dermatomyositis undergo malignancy screening?","volume":"9","author":"Khanna","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2411605","DOI":"10.1080\/07853890.2024.2411605","article-title":"Short-term efficiency of plasma exchange in combination with immunosuppressants and\/or biologics in the treatment of idiopathic inflammatory myopathy with rapidly progressive interstitial lung disease: A systematic review and meta-analysis","volume":"56","author":"Yang","year":"2024","journal-title":"Ann. Med."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Johnson, D., Van Eeden, C., Moazab, N., Redmond, D., Phan, C., Keeling, S., Gniadecki, R., Cohen Tervaert, J.W., and Osman, M. (2021). Nailfold Capillaroscopy Abnormalities Correlate with Disease Activity in Adult Dermatomyositis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.708432"},{"key":"ref_63","first-page":"69","article-title":"Dermatomyositis: Nailfold capillaroscopy patterns and a general survey","volume":"33","author":"Trevisan","year":"2024","journal-title":"Acta Dermatovenerol. Alp. Pannonica Adriat."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e16117","DOI":"10.1111\/ene.16117","article-title":"Disease spectrum of myopathies with elevated aldolase and normal creatine kinase","volume":"31","author":"Soontrapa","year":"2024","journal-title":"Euro J. Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Hodler, J., Kubik-Huch, R.A., and von Schulthess, G.K. (2021). Muscle Imaging. Musculoskeletal Diseases 2021\u20132024, Springer.","DOI":"10.1007\/978-3-030-71281-5"},{"key":"ref_66","first-page":"e88601","article-title":"Dermatomyositis: A Narrative Review of Skin as a Window to Muscle and Malignancy","volume":"17","author":"Cristofori","year":"2025","journal-title":"Cureus"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/cup.13880","article-title":"Increased MxA protein expression and dendritic cells in spongiotic dermatitis differentiates dermatomyositis from eczema in a single-center case-control study","volume":"48","author":"Zeidi","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5021\/ad.24.022","article-title":"Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures from Dermatologic Perspectives","volume":"36","author":"Kim","year":"2024","journal-title":"Ann. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of Intravenous Immune Globulin in Dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Yang, M., and Liu, J. (2025). Dermatomyositis following resection of thyroid and breast cancer: A case report and literature review. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1474481"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"152564","DOI":"10.1016\/j.semarthrit.2024.152564","article-title":"One-year survival benefit of plasma exchange in idiopathic inflammatory myositis patients with progressive interstitial lung disease-a systemic review and meta-analysis","volume":"69","author":"Tangborwornweerakul","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00296-024-05551-2","article-title":"Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: A case series and literature review on Janus kinase inhibitors for the disease","volume":"44","author":"Harada","year":"2024","journal-title":"Rheumatol. Int."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ma, C., Liu, M., Cheng, Y., Wang, X., Zhao, Y., Wang, K., and Wang, W. (2024). Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis\/dermatomyositis: A single-arm systemic meta-analysis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1382728"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e15201","DOI":"10.1111\/1756-185X.15201","article-title":"Perspectives in the treatment of interstitial lung disease accompanied with anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"27","author":"Tsuji","year":"2024","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s10067-025-07439-3","article-title":"Anti-mitochondrial antibody-positive inflammatory myopathy with multiple arrhythmias resistant to high-dose glucocorticoids and intravenous cyclophosphamide: A case-based review","volume":"44","author":"Mutoh","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Pinotti, C.S., Cannon, L., Dvergsten, J.A., and Wu, E.Y. (2023). Calcinosis in juvenile dermatomyositis: Updates on pathogenesis and treatment. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1155839"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"R\u00f3bert, L., B\u00e1nv\u00f6lgyi, A., L\u0151rincz, K., Holl\u00f3, P., and Hidv\u00e9gi, B. (2023). Systemic Sodium Thiosulfate as an Adjunct Treatment in Calcinosis: A Retrospective Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12247741"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/art.43066","article-title":"Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial","volume":"77","author":"Aggarwal","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum."}],"container-title":["Muscles"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2813-0413\/4\/4\/58\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:16:00Z","timestamp":1764954960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2813-0413\/4\/4\/58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":79,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["muscles4040058"],"URL":"https:\/\/doi.org\/10.3390\/muscles4040058","relation":{},"ISSN":["2813-0413"],"issn-type":[{"value":"2813-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}